Tarceva Average Treatment Duration Is Approximately Four Months, OSI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Market opportunity for Tarceva should be evaluated based on mean duration of therapy, which is “a little over four months,” rather than median progression free survival of roughly nine weeks, company says. OSI attempts to correct investor “confusion” about commercial opportunity for the Genentech/OSI lung cancer agent.
You may also be interested in...
OSI Shareholders File Class Action Suits Over Tarceva Data
OSI shareholders have filed several class-action lawsuits alleging the company made misleading claims about Tarceva prior to approval
OSI Shareholders File Class Action Suits Over Tarceva Data
OSI shareholders have filed several class-action lawsuits alleging the company made misleading claims about Tarceva prior to approval
Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.